Inactive Instrument

News Cyteir Therapeutics, Inc.

Equities

CYTT

US23284P1030

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Cyteir Therapeutics, Inc. Estimates Common Stock Liquidation Distributions	03-20	CI
Cyteir Therapeutics, Inc.(NasdaqGS:CYT) dropped from S&P TMI Index	03-19	CI
Cyteir Therapeutics, Inc.(OTCPK:CYTT) dropped from NASDAQ Composite Index	03-14	CI
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq	03-07	BU
Cyteir Therapeutics, Inc. Announces Resignation of Timothy Romberger from Board of Directors	12-07	CI
Cyteir Therapeutics, Inc. Announces Board Changes	12-05	CI
Cyteir Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
Cyteir Therapeutics - Ongoing Results from a Dose Expansion Cohort of CYT-0851 in Combination with Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile	13/10/23	AQ
Cyteir Therapeutics' Ovarian Cancer Combination Treatment Candidate Shows 91% Overall Disease Control in Phase 1 Study	12/10/23	MT
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile	12/10/23	BU
Cyteir Therapeutics, Inc. Presents Ongoing Results from a Dose Expansion Cohort of CYT-0851 in Combination with Capecitabine in Advanced Platinum-Resistant Ovarian Cancer	12/10/23	CI
Cyteir Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23	CI
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution	03/07/23	AQ
Top Midday Gainers	30/06/23	MT
Cyteir Therapeutics, Inc. Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution	30/06/23	CI
Cyteir Therapeutics to Discontinue CYT-0851 Development, Plans Dissolution, Liquidation of Assets; Shares Rise Pre-Bell	30/06/23	MT
Cyteir Therapeutics' Board Recommends Liquidation, Dissolution of Assets	30/06/23	MT
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution	30/06/23	BU
CYTEIR THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	05/06/23	AQ
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile	03/06/23	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cyteir Therapeutics, Inc.

Equities

CYTT

US23284P1030

Summary

Filters